SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator elysse1kittycat, sports guy, LODE MAKING ME RICH, lasers, AyeEye
Search This Board:
Last Post: 11/29/2015 10:00:27 PM - Followers: 653 - Board type: Free - Posts Today: 31

 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »

Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.


Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.




Press Releases






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#88104  Sticky Note I had to register just to make a comment. Enough-Already 08/26/15 05:35:48 PM
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#90676   This is the perfect scenario for a legal lasers 11/29/15 10:00:27 PM
#90675   Quote BS LOL, "BTW if this were the Captain Kirk 11/29/15 09:36:52 PM
#90674   BTW if this were the case, then the lasers 11/29/15 09:11:47 PM
#90673   Interesting that the transacted shares since Nov 10 lasers 11/29/15 09:00:17 PM
#90672   For Lasers information, he has got me thinking chuckanutman 11/29/15 08:34:03 PM
#90671   For me for Astellas or any company to elysse1kittycat 11/29/15 08:18:44 PM
#90670   As well $OCAT Blood Platelet Patents that held lasers 11/29/15 07:59:40 PM
#90669   Who would you feel most sorry for, a chuckanutman 11/29/15 07:40:23 PM
#90668   Quote BS LOL, "$OCAT +150 Patents + Patents Captain Kirk 11/29/15 07:18:53 PM
#90667   Historically speaking, I would love to see the elysse1kittycat 11/29/15 07:17:30 PM
#90666   $OCAT +150 Patents + Patents Appl will control lasers 11/29/15 07:06:54 PM
#90665   Quote BS LOL, "Astellas purchased OSI Pharmaceuticals for Captain Kirk 11/29/15 06:52:15 PM
#90664   If someone who knew nothing about the company elysse1kittycat 11/29/15 06:46:54 PM
#90663   Astellas purchased OSI Pharmaceuticals for $4.0 billion May lasers 11/29/15 06:36:53 PM
#90662   Quote LOL, "Astellas with cash on hand of Captain Kirk 11/29/15 06:21:00 PM
#90661   Quote BS LOL, "$OCAT shareholders should know within Captain Kirk 11/29/15 06:17:47 PM
#90660   Astellas with cash on hand of Yen lasers 11/29/15 06:13:52 PM
#90659   $OCAT shareholders should know within 2 weeks as lasers 11/29/15 05:45:27 PM
#90658   That seems right. elysse1kittycat 11/29/15 05:28:45 PM
#90656   IMo, the ballgame's over with Astellas, who it farviewhill 11/29/15 05:06:33 PM
#90655   Great point lasers. Retail shareholders may not have Titan V 11/29/15 04:41:02 PM
#90654   Astellas Standstill Provision lasers 11/29/15 04:25:24 PM
#90653   Achievements "OCATA Therapeutics" chuckanutman 11/29/15 03:54:54 PM
#90652   Question for someone: elysse1kittycat 11/29/15 03:54:24 PM
#90651   Since Astellas products pipeline is extremely poor due lasers 11/29/15 03:52:19 PM
#90647   Sold at $8.50!! elysse1kittycat 11/29/15 12:31:56 PM
#90646   Just curious but if i was buying your es1 11/29/15 09:32:52 AM
#90645   HIGHER BIDS? OcataMattaDingDong 11/28/15 10:21:10 PM
#90644   I agree;however, and correct me if I am elysse1kittycat 11/28/15 06:15:43 PM
#90643   There's no guarantee that a better competing offer farviewhill 11/28/15 05:56:57 PM
#90642   Understood. My point is that there is no guarantee elysse1kittycat 11/28/15 05:47:44 PM
#90641   No. Yhe point is it opens the door for farviewhill 11/28/15 05:42:21 PM
#90640   To change the famous expression a little to elysse1kittycat 11/28/15 05:25:23 PM
#90639   For those principled and believing posters and shareholders, farviewhill 11/28/15 05:17:38 PM
#90638   I would say is is more like Ocata elysse1kittycat 11/28/15 12:52:25 PM
#90637   LOL yes OCAT has Brilliant-Science. Those that did chuckanutman 11/28/15 12:44:35 PM
#90636   Quote BS LOL, "Are other bidders in the Captain Kirk 11/28/15 12:31:10 PM
#90635   Are other bidders in the wings? OCAT now chuckanutman 11/28/15 12:08:49 PM
#90634   How many people answered it and said 20, elysse1kittycat 11/28/15 11:59:55 AM
#90633   As I remember you did ask before and guy3 11/28/15 11:54:26 AM
#90632   I am not sure if I asked this elysse1kittycat 11/28/15 11:03:39 AM
#90631   Did Astellas reserve the right to "increase-the-Offer" to chuckanutman 11/28/15 10:31:37 AM
#90630   He has strong competition from Bogeyfree of that elysse1kittycat 11/28/15 12:20:30 AM
#90629   STEMDYNASTY: Wrong on Ocat about 99% of the time. OcataMattaDingDong 11/27/15 11:26:22 PM
#90628   OCAT: ABOVE 8.50 4 of 13 trading days. OcataMattaDingDong 11/27/15 11:20:57 PM
#90627   QUOTE BS LOL, CAPTIAN KIRK OcataMattaDingDong 11/27/15 11:13:54 PM
#90626   GILD continues to look for a new cornerstone north40000 11/27/15 10:49:42 PM
#90625   Two points. farviewhill 11/27/15 03:16:15 PM
#90624   I will say it one more time: elysse1kittycat 11/27/15 02:26:52 PM
#90623   $OCAT 5724 open interest Feb 19, 2016 $10 lasers 11/27/15 01:20:40 PM